Janssen has introduced AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet.
This innovative dual action tablet (DAT) combines two distinct therapeutic mechanisms: niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, an androgen biosynthesis inhibitor.
AKEEGA™ (niraparib and abiraterone acetate) marks a significant advancement in the treatment of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC) in patients with BRCA gene alterations.
AKEEGA™ offers hope for improved outcomes and survival for individuals with mCRPC and BRCA-positive mutations, addressing a previously unmet medical need.
This unique combination targets two critical drivers of cancer growth in patients with mCRPC and BRCA-positive mutations.
The approval of AKEEGA™ signifies a notable addition to the available treatment options for individuals with mCRPC. This advancement highlights the importance of personalized medicine and genetic testing in the field of oncology, particularly for prostate cancer patients.
Prostate cancer is a prevalent cancer type in the United States, with a considerable number of new cases and deaths projected for 2023. This underscores the urgent need for effective treatment strategies, especially for patients with aggressive forms of the disease, such as those with BRCA gene alterations.